2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer Trilaciclib, Saline (0.9% NaCl) - Limited Stage Small Cell Lung Cancer | Phase 3 | Recruiting | Pharmacosmos A/S | 120 | 2026-09-01 | 2026-10-02 |
| A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer Trilaciclib, Trilaciclib Placebo, Etoposide Injection - Myelosuppression | Phase 3 | Active not recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 106 | 2026-06-17 | 2026-10-19 |
| A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma. Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib, Tislelizumab, Cisplatin, Gemcitabine - Bladder Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 210 | 2025-10-01 | 2025-02-21 |
| Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients Trilaciclib, carboplatin, etoposideļ¼or Topotecan, placebo, carboplatin, etoposideļ¼or Topotecan - Extensive-stage Small-cell Lung Cancer | Phase 3 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 95 | 2021-05-25 | 2024-07-10 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) Trilaciclib, Placebo, Gemcitabine - TNBC - Triple-Negative Breast Cancer, Breast Cancer | Phase 3 | Completed | G1 Therapeutics, Inc. | 194 | 2021-05-14 | 2024-08-01 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Trilaciclib, Placebo - Colorectal Cancer Metastatic, Myelosuppression-Adult | Phase 3 | Terminated | G1 Therapeutics, Inc. | 326 | 2021-01-06 | 2024-11-26 |
Small Cell Lung Carcinoma (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
G1 Therapeutics, Inc. (2) · Jiangsu Simcere Pharmaceutical Co., Ltd. (2) · Pharmacosmos A/S (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
China (5) · United States (3) · Poland (2) · Spain (2) · Ukraine (2) · Australia (1) · Bulgaria (1) · France (1) · Georgia (1) · Hungary (1) · Italy (1) · Moldova (1) · Russia (1) · United Kingdom (1)
Tianxin Lin, Ph.D (1) · Ying Cheng, Doctor (1)